Literature DB >> 2570699

Renal and hormonal effects of alpha 1-adrenoceptor blockade by bunazosin in essential hypertension.

Y Hirata1, K Fukui, Y Dan, H Matsuoka, T Sugimoto, M Ishii.   

Abstract

The renal and hormonal effects of the alpha 1-adrenoceptor blocker bunazosin were examined in 6 patients with essential hypertension. Oral bunazosin for 4 to 12 weeks significantly decreased mean blood pressure by 10%, increased effective renal blood flow and creatinine clearance by 34% and 37%, respectively, the plasma norepinephrine concentration was elevated by 60%, and the plasma atrial natriuretic peptide level was lowered by 22%. The plasma renin activity and aldosterone concentration were unchanged. Thus, a moderate reduction in blood pressure was produced by bunazosin treatment while maintaining renal perfusion.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2570699     DOI: 10.1007/BF00637738

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  10 in total

1.  Hemodynamics of hypertension.

Authors:  E D FREIS
Journal:  Physiol Rev       Date:  1960-01       Impact factor: 37.312

2.  Evaluation of renal resistances, with special reference to changes in essential hypertension.

Authors:  D M GOMEZ
Journal:  J Clin Invest       Date:  1951-10       Impact factor: 14.808

3.  alpha-Adrenoceptor blocking properties of a new antihypertensive agent, 2-[4-(n-butyryl)-homopiperazine-1-yl]-4-amino-6,7-dimethoxyquinazoline (E-643).

Authors:  T Shoji; Y Daiku; T Igarashi
Journal:  Jpn J Pharmacol       Date:  1980-12

4.  Evidence for alpha-1 adrenergic receptor regulation of atriopeptin release from the isolated rat heart.

Authors:  M G Currie; W H Newman
Journal:  Biochem Biophys Res Commun       Date:  1986-05-29       Impact factor: 3.575

Review 5.  Renal vascular tone in essential and secondary hypertension: hemodynamic and angiographic responses to vasodilators.

Authors:  N K Hollenberg; D F Adams; H Solomon; W R Chenitz; B M Burger; H L Abrams; J P Merrill
Journal:  Medicine (Baltimore)       Date:  1975-01       Impact factor: 1.889

6.  Prazosin and renal hemodynamics: arteriolar vasodilation during therapy of essential hypertension in man.

Authors:  R A Preston; D T O'Connor; R A Stone
Journal:  J Cardiovasc Pharmacol       Date:  1979 May-Jun       Impact factor: 3.105

7.  Plasma concentrations of alpha-human atrial natriuretic polypeptide and cyclic GMP in patients with heart disease.

Authors:  Y Hirata; M Ishii; H Matsuoka; T Sugimoto; M Iizuka; Y Uchida; T Serizawa; H Sato; O Kohmoto; T Mochizuki
Journal:  Am Heart J       Date:  1987-06       Impact factor: 4.749

8.  Renal function and hemodynamic studies in low- and normal-renin essential hypertension.

Authors:  J H Bauer; C S Brooks; R N Burch
Journal:  Arch Intern Med       Date:  1982-07

9.  Role of the renal sympathetic nerves in the development and maintenance of hypertension in the spontaneously hypertensive rat.

Authors:  S R Winternitz; R E Katholi; S Oparil
Journal:  J Clin Invest       Date:  1980-11       Impact factor: 14.808

10.  Elevated plasma catecholamines in hypertensives with primary glomerular diseases.

Authors:  M Ishii; T Ikeda; M Takagi; T Sugimoto; K Atarashi; T Igari; Y Uehara; H Matsuoka; Y Hirata; K Kimura; T Takeda; S Murao
Journal:  Hypertension       Date:  1983 Jul-Aug       Impact factor: 10.190

  10 in total
  1 in total

1.  Effects of arotinolol on exercise capacity and humoral factors during exercise in normal subjects.

Authors:  T Mori; K Handa; Y Terao; H Tanaka; A Kiyonaga; M Shindo; A Matsunaga; J Sasaki; K Arakawa
Journal:  Cardiovasc Drugs Ther       Date:  1992-08       Impact factor: 3.727

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.